Horizon's dazodalibep meets further endpoint in Sjögren's syndrome study

Horizon Therapeutics (Nasdaq: HZNP), a biotech focused on rare, autoimmune and severe inflammatory diseases that is about to be acquired by US biotech major Amgen (Nasdaq: AMGN), has announced an update on its pipeline.

The Ireland-headquartered company has revealed that the primary endpoint was met for the second population in its Phase II trial evaluating dazodalibep for the treatment of Sjögren’s syndrome.

"There are currently no disease-modifying Food and Drug Administration-approved treatments for Sjögren’s"Positive results in the first patient population were announced in September of last year. Dazodalibep is the only medicine in development to achieve the primary endpoint in both patient populations in a Phase II trial.